|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Jemal A, Thun MJ, Ward EE, et al:
Mortality from leading causes by education and race in the United
States, 2001. Am J Prev Med. 34:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Erridge SC, Møller H, Price A and Brewster
D: International comparisons of survival from lung cancer: pitfalls
and warnings. Nat Clin Pract Oncol. 4:570–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiller JH, Harrington D, Belani CP, et
al: Eastern Cooperative Oncology Group: Comparison of four
chemotherapy regimens for advanced non-small-cell lung cancer. N
Engl J Med. 346:92–98. 2002. View Article : Google Scholar
|
|
5
|
Kim HK, Choi IJ, Kim CG, et al: A gene
expression signature of acquired chemoresistance to cisplatin and
fluorouracil combination chemotherapy in gastric cancer patients.
PLoS One. 6:e166942011. View Article : Google Scholar
|
|
6
|
Zhang CX and Lippard SJ: New metal
complexes as potential therapeutics. Curr Opin Chem Biol.
7:481–489. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Rijt SH and Sadler PJ: Current
applications and future potential for bioinorganic chemistry in the
development of anticancer drugs. Drug Discov Today. 14:1089–1097.
2009.PubMed/NCBI
|
|
8
|
Gasser G, Ott I and Metzler-Nolte N:
Organometallic anticancer compounds. J Med Chem. 54:3–25. 2011.
View Article : Google Scholar
|
|
9
|
Sanghamitra NJ, Phatak P, Das S, Samuelson
AG and Somasundaram K: Mechanism of cytotoxicity of copper (I)
complexes of 1,2-bis(diphenylphosphino)ethane. J Med Chem.
48:977–985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seelig MH, Berger MR and Keppler BK:
Antineoplastic activity of three ruthenium derivatives against
chemically induced colorectal carcinoma in rats. J Cancer Res Clin
Oncol. 118:195–200. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dyson PJ and Sava G: Metal-based
antitumour drugs in the post genomic era. Dalton Trans. 1929–1933.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marzano C, Pellei M, Tisato F and Santini
C: Copper complexes as anticancer agents. Anticancer Agents Med
Chem. 9:185–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chaviara AT, Christidis PC, Papageorgiou
A, et al: In vivo anticancer, anti-inflammatory, and toxicity
studies of mixed-ligand Cu(II) complexes of dien and its Schiff
dibases with heterocyclic aldehydes and 2-amino-2-thiazoline.
Crystal structure of [Cu(dien)(Br)(2a-2tzn)](Br)(H(2)O)]. J Inorg
Biochem. 99:2102–2109. 2005.PubMed/NCBI
|
|
14
|
Jamieson ER and Lippard SJ: Structure,
Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev.
99:2467–2498. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tardito S, Bussolati O, Maffini M, et al:
Thioamido coordination in a thioxo-1,2,4-triazole copper(II)
complex enhances nonapoptotic programmed cell death associated with
copper accumulation and oxidative stress in human cancer cells. J
Med Chem. 50:1916–1924. 2007. View Article : Google Scholar
|
|
16
|
Egan D, O’Kennedy R, Moran E, et al: The
pharmacology, metabolism, analysis, and applications of coumarin
and coumarin-related compounds. Drug Metab Rev. 22:503–529. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pochet L, Doucet C, Schynts M, et al:
Esters and amides of
6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as
inhibitors of alpha-chymotrypsin: significance of the ‘aromatic’
nature of the novel ester-type coumarin for strong inhibitory
activity. J Med Chem. 39:2579–2585. 1996.PubMed/NCBI
|
|
18
|
Kostova I, Raleva S, Genova P and Argirova
R: Structure-Activity Relationships of Synthetic Coumarins as HIV-1
Inhibitors. Bioinorg Chem Appl. 2006:682742006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kirkiacharian S, Thuy DT, Sicsic S, et al:
Structure-activity relationships of some
3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors.
Farmaco. 57:703–708. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu D, Suzuki M, Xie L, Morris-Natschke SL
and Lee KH: Recent progress in the development of coumarin
derivatives as potent anti-HIV agents. Med Res Rev. 23:322–345.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng WR, Wu JG and Long LS: Lanthanide
complexes of di(4-hydroxycoumarinyl-3)-acetic acid and their
anticoagulant action. Bul Soc Chim Belg. 101:439–443. 1992.
View Article : Google Scholar
|
|
22
|
Dobson AJ and Gerkin RE:
Coumarin-3-carboxylic acid. Acta Crystallogr C. 52:3081–3083. 1996.
View Article : Google Scholar
|
|
23
|
Bagihalli GB, Avaji PG, Patil SA and
Badami PS: Synthesis, spectral characterization, in vitro
antibacterial, antifungal and cytotoxic activities of Co(II),
Ni(II) and Cu(II) complexes with 1,2,4-triazole Schiff bases. Eur J
Med Chem. 43:2639–2649. 2008.
|
|
24
|
Jia L, Xu XM, Xu J, et al: Synthesis,
characterization, cytotoxic activities, and DNA-binding studies of
ternary copper(II) complexes with new coumarin derivatives. Chem
Pharm Bull (Tokyo). 58:1003–1008. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
May P and May E: Twenty years of p53
research: structural and functional aspects of the p53 protein.
Oncogene. 18:7621–7636. 1999.PubMed/NCBI
|
|
26
|
Cheah PL and Looi LM: p53: an overview of
over two decades of study. Malays J Pathol. 23:9–16.
2001.PubMed/NCBI
|
|
27
|
Friesen C, Herr I, Krammer PH and Debatin
KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in
drug-induced apoptosis in leukemia cells. Nat Med. 2:574–577. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brown JM and Wouters BG: Apoptosis, p53,
and tumor cell sensitivity to anticancer agents. Cancer Res.
59:1391–1399. 1999.PubMed/NCBI
|
|
29
|
Goodsell DS: The molecular perspective:
Bcl-2 and apoptosis. Stem Cells. 20:355–356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cory S and Adams JM: The Bcl2 family:
regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Douillard JY, Eckardt J and Scagliotti GV:
Challenging the platinum combinations in the chemotherapy of NSCLC.
Lung Cancer. 38(Suppl 4): 21–28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stewart DJ: Mechanisms of resistance to
cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007.
View Article : Google Scholar : PubMed/NCBI
|
